Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vicept Acquired By Allergan For $75M Upfront

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergan adds to its dermatology portfolio with the acquisition of closely-held Vicept.
Advertisement

Related Content

Galderma’s Mirvaso Joins Rosacea Market With Indication For Facial Erythema
Financings Of The Fortnight: Could California’s Regenerative Medicine Ballot Initiative Pass Today?
Vicept Management, VCs Team Up Again To Launch Aclaris With $21M
Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments
Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Takeda's $13.6 Bil. Nycomed Buy Meets Multiple Strategic, Financial Imperatives
Deals Of The Week: Eisai/Epizyme, AstraZeneca/Galderma, Evotec/Harvard
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS072536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel